Annie Borch
Overview
Explore the profile of Annie Borch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skadborg S, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1202-1220.
PMID: 38885356
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis. Although immunotherapy is being explored as a potential treatment option for patients with GBM, it is unclear whether systemic immunotherapy...
2.
Mork S, Skadborg S, Albieri B, Draghi A, Bol K, Kadivar M, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38782542
Background: Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01,...
3.
Borch A, Carri I, Reynisson B, Garcia Alvarez H, Munk K, Montemurro A, et al.
Front Immunol
. 2024 Apr;
15:1360281.
PMID: 38633261
Background: Mutation-derived neoantigens are critical targets for tumor rejection in cancer immunotherapy, and better tools for neoepitope identification and prediction are needed to improve neoepitope targeting strategies. Computational tools have...
4.
Borch A, Bjerregaard A, de Lima V, Ostrup O, Yde C, Eklund A, et al.
Front Genet
. 2023 Apr;
14:1058605.
PMID: 37035751
Immune checkpoint inhibition for the treatment of cancer has provided a breakthrough in oncology, and several new checkpoint inhibition pathways are currently being investigated regarding their potential to provide additional...
5.
Holm J, Funt S, Borch A, Munk K, Bjerregaard A, Reading J, et al.
Nat Commun
. 2022 Apr;
13(1):1935.
PMID: 35410325
CD8 T cell reactivity towards tumor mutation-derived neoantigens is widely believed to facilitate the antitumor immunity induced by immune checkpoint blockade (ICB). Here we show that broadening in the number...
6.
Kristensen N, Heeke C, Tvingsholm S, Borch A, Draghi A, Crowther M, et al.
J Clin Invest
. 2021 Nov;
132(2).
PMID: 34813506
BACKGROUNDNeoantigen-driven recognition and T cell-mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T...
7.
Schaap-Johansen A, Vujovic M, Borch A, Hadrup S, Marcatili P
Front Immunol
. 2021 Oct;
12:712488.
PMID: 34603286
T cells play a crucial role in controlling and driving the immune response with their ability to discriminate peptides derived from healthy as well as pathogenic proteins. In this review,...
8.
Saini S, Orskov A, Bjerregaard A, Unnikrishnan A, Holmberg-Thyden S, Borch A, et al.
Nat Commun
. 2020 Nov;
11(1):5660.
PMID: 33168830
Human endogenous retroviruses (HERV) form a substantial part of the human genome, but mostly remain transcriptionally silent under strict epigenetic regulation, yet can potentially be reactivated by malignant transformation or...
9.
Hansen U, Ramskov S, Bjerregaard A, Borch A, Andersen R, Draghi A, et al.
Front Immunol
. 2020 Apr;
11:373.
PMID: 32226429
Mutation-derived neoantigens are important targets for T cell-mediated reactivity toward tumors and, due to their unique tumor expression, an attractive target for immunotherapy. Neoepitope-specific T cells have been detected across...
10.
Araujo B de Lima V, Borch A, Hansen M, Draghi A, Spanggaard I, Rohrberg K, et al.
Cytotherapy
. 2020 Mar;
22(4):204-213.
PMID: 32201034
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape and our perception of interactions between the immune system and tumor cells. Despite remarkable progress, disease relapse and primary...